Navigation Links
Sangart, Inc. Completes Series F Funding Round
Date:3/12/2009

SAN DIEGO, March 12 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen therapeutics, today announced the receipt of approximately $50 million in funding from existing investors. This investment results from the exercise of warrants issued by Sangart as part of a Series F financing round initiated in 2007. The most recent investment brings the total funding under the Series F round to approximately $100 million. Proceeds from this warrant exercise will be used to fund further clinical development of Sangart's MP4 oxygen therapeutic products.

"We are excited to see this continued support from our investors and believe it demonstrates the potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding contributes significantly to our efforts to further the clinical research and development of our MP4 oxygen therapeutic products."

About MP4 Oxygen Therapeutics

The MP4 molecule is the basis for Sangart's oxygen therapeutic product platform. The MP4 molecule is created using unique polyethylene glycol conjugation with human hemoglobin and was specifically designed to the optimal molecular size, viscosity, oxygen affinity and diffusion potential to target oxygen delivery to tissues at risk of oxygen deprivation based on experiments with artificial capillaries and in several different animal models. Extensive research and testing demonstrates that this approach optimizes oxygen delivery while minimizing the side effects that plagued earlier generation products.

About Sangart

Sangart, Inc. is a privately held biopharmaceutical company focused on being the global scientific, clinical and commercial leader in oxygen-therapeutic agents, providing innovative products to patients in need. Sangart was founded based on technologies developed during more than two deca
'/>"/>

SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
2. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
3. Cardium Completes $3.5 Million Credit Facility
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
6. CIRM Completes Briefing Visit to Stemedica Cell Technologies
7. INVO Bioscience Completes Reverse Merger
8. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
9. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. New Generation Biofuels Completes Construction of Baltimore Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014  Lisa Kulik saw fireworks for the first ... thanks to a groundbreaking retinal implant co-invented by ... at the University of Southern California (USC) Eye Institute. ... Ariz. resident who has retinitis pigmentosa, a ... On June 2, she became the first person west ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... JUNCTION, N.J. , Aug. 27, 2014 ... innovative drug delivery technologies, today announced that it has ... Jersey Business & Industry Association,s 2014 Awards for ... were selected by an independent panel of judges from ... company volunteers. Award winners will be honored at a ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... FREMONT, Calif., Dec. 14 Vermillion, Inc. (Pink Sheets: ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice President, Research ... board of directors upon confirmation of Vermillion,s bankruptcy plan. ... and development experience in diagnostics and biotechnology," said Gail ...
... , , , NATICK, Mass., Dec. ... announced the completion of a public offering of $2 billion aggregate ... statement. The public offering consists of $850 million of 4.50 ... due January 2020 and $300 million of 7.375 percent notes due ...
... ... the delivery of Brookfield Engineering’s Powder Flow Tester – helping Brookfield move from sheet ... , ... December 14, 2009 -- ThermoFab, a US-based thermoforming company, has completed the delivery of ...
Cached Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
(Date:8/26/2014)... of harmful bacteria, biofilms make the treatment of ... biofilm pose a significant health risk due to ... biofilm-protected bacteria account for some 80 percent of ... to 1,000 times more resistant to antibiotics than ... have stumbled onto a magic bullet," said David ...
(Date:8/26/2014)... succeeded in obtaining an unprecedented view of a ... a range of neurological illnesses, including Alzheimer,s disease, ... associated with stroke. , The team of biologists ... Department of Energy,s Advanced Photon Source at Argonne ... the intact NMDA (N-methyl, D-aspartate) receptor should serve ...
(Date:8/26/2014)... endemic tree has for the last 31 years been incorrectly ... and small trees. A New Zealand botanist has completed a ... diversity behind what was long considered a single tree species. ... PhytoKeys . , Known to botanists as ... discoveries made in the north-western South Island of New Zealand ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 2Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3
... life in higher animals, vitamin D, once linked to only ... as a major player in contributing to overall human health, ... on vitamin D. In a paper published in the ... Nutrition , Norman identifies vitamin D,s potential for contributions ...
... Carolina State University is leading to a new kind ... from freshwater ponds, instead of from the sea. ... crabs look and taste just like their ocean-raised brethren. ... at historic lows since 2000. Dr. Dave Eggleston, director ...
... develop sustainable energy systems while reducing the harmful ... phased out over the next century. This optimistic ... technologies such as biomimetics and Dye Sensitized solar ... or storing solar energy, and nanocatalysis develops efficient ...
Cached Biology News:Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 2Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 3Turning freshwater farm ponds into crab farms 2Europe rallies behind nanotechnology to wean world from fossil fuels 2Europe rallies behind nanotechnology to wean world from fossil fuels 3Europe rallies behind nanotechnology to wean world from fossil fuels 4
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... KLH-conjugated, synthetic peptide corresponding ... of mouse p19ARF. The ... acids 62-75. Clone 5-C3-1. ... by immunoblot. Stability ...
Biology Products: